CRA was retained to develop a technology strategy to support improvements in drug discovery and development productivity. We profiled the company’s existing technology positions and assessed technology opportunities for its future. We created strategy options, supporting them with insights into technology and supplier evolution, and we considered how they could adopt new technology. Finally, CRA supported the key implementation decisions to divest existing technology, license/acquire new technology and monitor/experiment with emerging technology
SAF to be used in Singapore departing flights from 2026
In this article, Marakon’s Rod Davies shares his thoughts on Singapore’s commitment to mandate the use of Sustainable Aviation Fuel (SAF) for departing...